Aardvark Therapeutics, Inc.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic
Funding history
About Aardvark Therapeutics, Inc.
How much funding has Aardvark Therapeutics, Inc. raised?
Aardvark Therapeutics, Inc. has raised $85.0M in total funding. The most recent round was Series B.
Where is Aardvark Therapeutics, Inc. headquartered?
Aardvark Therapeutics, Inc. is headquartered in San Diego, CA.
What does Aardvark Therapeutics, Inc. do?
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic
What problem does Aardvark Therapeutics, Inc. solve?
Hunger is a distinct neurologic drive (separate from appetite) that underlies metabolic diseases like obesity and hyperphagia in rare diseases, and isn't well addressed by current treatments.
What's Aardvark Therapeutics, Inc.'s solution?
Aardvark is a clinical-stage biopharmaceutical company developing oral small-molecule drugs, led by ARD-101, designed to inhibit hunger and treat metabolic disease.
What makes Aardvark Therapeutics, Inc. different?
ARD-101 acts locally in the digestive tract by activating bitter taste receptors (TAS2Rs) to trigger release of satiety hormones and suppress hunger via gut-brain signaling, rather than acting systemically.
What makes Aardvark Therapeutics, Inc. notable?
San Diego-based Aardvark Therapeutics completed its IPO in February 2025, raising $97.9M in gross proceeds, after an $85M Series C led by Decheng Capital.
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.